 |
|
Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
October 24, 2007Phase 2 Consortium clinical trial shows promising results
SAN FRANCISCO -- Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.
Findings from this Phase 2 Consortium (P2C) clinical trial were presented by the study's primary investigator, Keith Bible, M.D., Ph.D., at the Molecular Targets and Cancer Therapeutics International Conference, a jointly-sponsored symposium of the American Association for Cancer Research, National Cancer Institute and the European Organization for Research and Treatment of Cancer.
"We are encouraged by the interim results of this trial," says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. "Platinum-resistant ovarian cancer responds poorly to traditional therapies, and we've been working toward developing more effective treatments for this disease. This combination looks very promising."
More than 22,400 women in the United States will be diagnosed with ovarian cancer this year, according to the American Cancer Society, and nearly 15,300 women will die from it. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents).
In this study, the researchers evaluated a combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers. The researchers found in earlier preclinical studies that flavopiridol significantly boosts the anti-cancer effects of cisplatin, and later conducted a Phase I clinical trial to pilot the combination in patients (KC Bible et al, Clinical Cancer Research, 11:5935, 2005). The present Phase II trial was designed to extend this work and better determine this therapy's effectiveness against platinum-resistant cancers.
Dr. Bible and his co-investigators treated 18 platinum-resistant Caucasian patients with this combination therapy. Of the 18 patients, all of whom were receiving the therapy as a second-line treatment after disease progression, one patient experienced complete response (all signs of cancer gone) and five other patients experienced partial responses (tumor regression). The 33 percent overall response rate (6 of 18 patients) is about twice as high as seen using traditional chemotherapy regimens.
The researchers also offered the combination therapy to five patients with platinum-sensitive (original therapy resulted in no recurrence for greater than 12 months) ovarian cancer. Of these women, one experienced complete response and three others partial response.
"We now need to expand this trial to validate these interim results in additional patients," says Dr. Bible. "We're also looking for ways to further boost the anti-cancer effects of the combination, in hopes of developing even more effective approaches to ovarian cancer."
Mayo Clinic
"We are encouraged by the interim results of this trial," says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. "Platinum-resistant ovarian cancer responds poorly to traditional therapies, and we've been working toward developing more effective treatments for this disease. This combination looks very promising."
More than 22,400 women in the United States will be diagnosed with ovarian cancer this year, according to the American Cancer Society, and nearly 15,300 women will die from it. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents).
In this study, the researchers evaluated a combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers. The researchers found in earlier preclinical studies that flavopiridol significantly boosts the anti-cancer effects of cisplatin, and later conducted a Phase I clinical trial to pilot the combination in patients (KC Bible et al, Clinical Cancer Research, 11:5935, 2005). The present Phase II trial was designed to extend this work and better determine this therapy's effectiveness against platinum-resistant cancers.
Dr. Bible and his co-investigators treated 18 platinum-resistant Caucasian patients with this combination therapy. Of the 18 patients, all of whom were receiving the therapy as a second-line treatment after disease progression, one patient experienced complete response (all signs of cancer gone) and five other patients experienced partial responses (tumor regression). The 33 percent overall response rate (6 of 18 patients) is about twice as high as seen using traditional chemotherapy regimens.
The researchers also offered the combination therapy to five patients with platinum-sensitive (original therapy resulted in no recurrence for greater than 12 months) ovarian cancer. Of these women, one experienced complete response and three others partial response.
"We now need to expand this trial to validate these interim results in additional patients," says Dr. Bible. "We're also looking for ways to further boost the anti-cancer effects of the combination, in hopes of developing even more effective approaches to ovarian cancer."
Mayo Clinic
Ovarian Cancer Current Events and Ovarian Cancer News RSSFDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding
The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.
Metals could forge new cancer drug
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.
Breast cancer patients with high risk gene diagnosed 6 years earlier than generation before
Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center.
Cancer Predisposition From Gene Variant Shows Strong Gender Bias
Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.
Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects
Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services.
Scientists from University of Hawaii at Manoa find genetic marker
A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom.
New treatment in sight for ovarian cancer
In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells.
Young early stage ovarian cancer patients can preserve fertility
A new study finds that young women with early-stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease.
Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells
The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses.
More Ovarian Cancer Current Events and Ovarian Cancer News Articles
 |
Beating Ovarian Cancer: How To Overcome The Odds And Reclaim Your Life by Chris Bledy (Author) A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to healing. |
 |
Ovarian Cancer Awareness "Unite to Fight" Wristband Adult Size by sci Ovarian Cancer Awareness "Unite To Fight" Wristband adult size |
 |
A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book) by F. J. Montz MD KM FACOG FACS (Author), Robert E. Bristow MD FACOG (Author), Paula J. Anastasia RN MN OCN (Assistant) This comprehensive guide to ovarian cancer offers a wealth of information to ease the physical, emotional, and psychic suffering of women with the disease. The authors -- two Johns Hopkins gynecologic oncologists and a gynecologic-oncology clinical nurse -- put particular emphasis on the concept of "survivorship," or living life well in the face of daunting uncertainties. They stress the importance of self-determination: the right of each patient to be informed, involved, and in control of her care. Up-to-date information on diagnosis and treatment, including surgery, chemotherapy, radiation, pain management, and alternative therapies, forms the core of the book. But the authors' immense clinical experience also means they understand what women worry about and care about, and... |
 |
Ovarian Cancer Awareness 8" Ribbon Car Magnet by sci Ovarian Cancer Awareness 8" Ribbon Car Magnet |
 |
L'Oréal Paris Color of Hope OCRF (Ovarian Cancer Research Fund) Fundraising Sterling Silver Pavé CZ Bracelet by Netaya Sterling beauty with an equally beautiful message. Its new, its exclusive and its absolutely beautiful. LOreal Paris is proud to present the Color of Hope Bracelet, a fundraising campaign, with 100% of all net profits ($5.00 per bracelet) benefiting The Ovarian Cancer Research Fund (OCRF). Whether viewed as a circle representing life, endurance, love or seen as an "O" for ovarian cancer, the bracelet is a simple way for women everywhere to visibly and tangibly help in the fight against one of the world's most deadly of women's cancers. The exclusive sterling silver Color of Hope bracelet features a rolo design chain with an "O" toggle clasp, adorned with pave cubic zirconias to give a beautiful brilliance. And to ensure that all women can adorn their wrists, the bracelet... |
 |
Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others by Ayala Miron (Author) "All of the research has reinforced that ovarian cancer is not a silent disease as was once thought and as is shown quite eloquently in this collection of stories.... The value of this collection of stories is that it helps raise awareness about symptoms, need for patient persistence, and the importance of being treated by a gynecologic oncologist." Barbara A. Goff, MD Professor and Co-Director, Division of Gynecologic Oncology University of Washington School of Medicine Women of ages 17 to 78 join to tell their true stories. Find out about the lessons they have learned along their ovarian cancer journeys; from symptoms to diagnosis, trough treatments, and survival. Ovarian cancer facts: Occurs in 1 out of 57 women 89% have symptoms at the early stages... |
 |
100 Questions & Answers About Ovarian Cancer, Second Edition by Don S. Dizon (Author) Whether you're a newly diagnosed ovarian cancer patient, a survivor, or a friend or relative of either, this book offers help. Completely updated, the new second edition of 100 Questions & Answers About Ovarian Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a gynecologic oncologist and a gynecologic surgeon, with actual patient commentary, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease. |
 |
Ovarian Cancer Awareness Long Sleeve T-shirt Large White by Shop Zeus |
 |
Ovarian Cancer Awareness Teal Ribbon Crystal Heart Necklace by CharmingChick This is a beautiful new teal ribbon heart charm necklace that is the perfect way to show your support for Ovarian Cancer Awareness. The pendant measures about 5/8 of an inch tall and is made of genuine sterling silver. It has stunning teal Swarovski Crystal embedded in the front. Box chain measures about 16 inches long. This teal ribbon necklace would make a great gift or is a wonderful way to remember a loved one with Ovarian Cancer. |
 |
I Fight Like A Girl - Ovarian Cancer Awareness Mug by GiftsForYouNow.com I Fight Like A Girl Personalized Coffee Mug for Ovarian Cancer AwarenessFight Like A Girl with Love & Hope against Ovarian Cancer with this uniquely Personalized Coffee Mug. A warm mug of coffee and great conversation between girls helps heal the soul. Our personalized coffee mug is dishwasher safe, and holds 11 oz. Personalize your Coffee Mug with any name. September is Ovarian Cancer Awareness Month. Share what you know! |
| © 2009 BrightSurf.com |